BCRX
BioCryst Pharmaceuticals Inc.
$7.70
-$0.26(-3.27%)
48
Overall
--
Value
36
Tech
60
Quality
Market Cap
$1.62B
Volume
6.62M
52W Range
$6.02 - $11.31
Target Price
$16.82
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $48.3M | $26.4M | $25.2M | $20.7M | $48.8M | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | ||
| Total Revenue | $6.3M | $2.3M | $25.2M | $20.7M | $48.8M | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-1.4M | $-2.3M | $-1.1M | -- | $3.7M | $1.7M | $7.3M | $6.6M | $4.5M | $12.3M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $46.9M | $24.1M | $-1.1M | $20.7M | $45.1M | $16.1M | $149.9M | $264.2M | $326.9M | $438.2M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $86.3M | $72.7M | $81.5M | $114.9M | $144.6M | $190.9M | $327.6M | $412.7M | $430.5M | $440.8M | ||
| Research & Development | $72.8M | $61.0M | $67.0M | $84.9M | $107.1M | $123.0M | $208.8M | $253.3M | $216.6M | $174.6M | ||
| Research Expense | $72.8M | $61.0M | $67.0M | $84.9M | $107.1M | $123.0M | $208.8M | $253.3M | $216.6M | $174.6M | ||
| Selling, General & Administrative | $13.0M | $11.3M | $13.9M | $29.5M | $37.1M | $67.9M | $118.8M | $159.4M | $213.9M | $266.1M | ||
| Selling & Marketing Expenses | $13.0M | $11.3M | $13.9M | -- | -- | $6.6M | $5.7M | $14.9M | $14.4M | $13.6M | ||
| General & Administrative Expenses | $-664.0K | $-721.0K | $-617.0K | $29.5M | $37.1M | $67.9M | $118.8M | $159.4M | $213.9M | $266.1M | ||
| Promotion & Advertising | $-103.0K | -- | -- | -- | -- | $6.6M | $5.7M | $14.9M | $14.4M | $13.6M | ||
| Salaries & Wages | $-9.7M | $-8.5M | $-12.6M | -- | -- | $14.8M | -- | -- | $55.6M | $65.4M | ||
| Depreciation & Amortization | $-180.0K | $-483.0K | $-704.0K | $-770.0K | $724.0K | $748.0K | $777.0K | $1.4M | $1.7M | $1.2M | ||
| Depreciation & Amortization | $-180.0K | $-483.0K | $-704.0K | $-770.0K | $724.0K | $748.0K | $777.0K | $1.4M | $1.7M | $1.2M | ||
| Amortization | $-439.0K | $-558.0K | $-876.0K | $-885.0K | $1.3M | $2.4M | -- | $816.0K | $1.2M | $1.8M | ||
| Other Operating Expenses | $528.0K | $402.0K | $560.0K | $471.0K | $375.0K | $-1.0M | $-1.5M | $-4.1M | $-825.0K | $-353.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-39.4M | $-48.6M | $-82.6M | $-94.2M | $-99.5M | $-174.8M | $-177.7M | $-148.4M | $-103.7M | $-2.5M | ||
| EBITDA | $-36.6M | $-47.1M | $-55.5M | $-90.3M | $-96.8M | $-166.7M | $-121.7M | $-143.9M | $-234.6M | $12.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $5.2M | $6.5M | $8.6M | $9.2M | $11.9M | $14.5M | $59.3M | $99.1M | $201.0K | $98.5M | ||
| Intinc | $535.0K | $793.0K | $1.0M | $2.3M | $1.9M | -- | -- | -- | $15.8M | $14.7M | ||
| Net Non-Operating Interest Income/Expense | $-4.7M | $-5.7M | $-7.5M | $-6.9M | $-11.9M | $-14.5M | $-59.3M | $94.0M | $15.8M | $14.7M | ||
| Gain on Sale of Securities | $1.1M | $-843.0K | $-821.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-1.1M | $843.0K | $-24.4M | -- | -- | $2.0M | $-55.8M | $-2.0M | $29.0M | -- | ||
| Other Special Charges | -- | -- | $25.2M | -- | -- | $-2.0M | $55.8M | -- | $-29.0M | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | -- | $-1.5M | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $1.5M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-37.8M | $-48.7M | $-57.2M | $-92.1M | $-98.9M | $-170.9M | $-122.5M | $-145.3M | $-226.0M | $11.6M | ||
| Pre-Tax Income | $-43.0M | $-55.1M | $-65.8M | $-101.3M | $-110.8M | $-182.8M | $-181.8M | $-244.4M | $-226.2M | $-87.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-1.0M | $-1.1M | $-71.2M | $-18.0K | $-1.6M | $-2.5M | $2.3M | $2.7M | $310.0K | $1.9M | ||
| NET INCOME | ||||||||||||
| Net Income | $-43.0M | $-55.1M | $-65.8M | $-101.3M | $-108.9M | $-182.8M | $-184.1M | $-247.1M | $-226.5M | $-88.9M | ||
| Net Income (Continuing Operations) | $-43.0M | $-55.1M | $-65.8M | $-101.3M | $-108.9M | $-182.8M | $-184.1M | $-247.1M | $-226.5M | $-88.9M | ||
| Net Income (Discontinued Operations) | $-43.0M | $-55.1M | $-65.8M | $-101.3M | $-108.9M | $-182.8M | $-184.1M | $-247.1M | $-226.5M | $-88.9M | ||
| Net Income (Common Stockholders) | $-43.0M | $-55.1M | $-65.8M | $-101.3M | $-108.9M | $-182.8M | $-184.1M | $-247.1M | $-226.5M | $-88.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-185.4M | -- | -- | $-177.2M | -- | ||
| TOTALS | ||||||||||||
| Total Expenses | $85.0M | $70.4M | $80.3M | $114.9M | $148.3M | $192.6M | $334.9M | $419.3M | $434.9M | $453.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $172.1M | $73.5M | $84.3M | $103.3M | $115.8M | $537.7M | $178.7K | $185.9M | $192.2M | $206.7M | ||
| Average Shares Outstanding (Diluted) | $72.9M | $73.7M | $84.5M | $103.2M | $115.6M | $167.3M | $179.1M | $185.9M | $192.2M | $206.7M | ||
| Shares Outstanding | $73.6M | $74.0M | $98.6M | $110.2M | $154.2M | $177.2M | $184.7M | $188.5M | $206.1M | $209.0M | ||
| Basic EPS | $-0.25 | -- | -- | $-0.98 | $-0.94 | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-0.98 | $-0.94 | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | ||
| Diluted EPS | $-0.59 | $-0.75 | $-0.78 | $-0.98 | $-0.94 | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-1.03 | $-1.33 | $-1.18 | $-0.43 | ||
| OTHER METRICS | ||||||||||||
| Acquired In Process Rn D Income | $39.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Income From Other Gains Losses | -- | -- | -- | -- | $1.9M | -- | -- | -- | -- | -- | ||
| Other Gand A | $-664.0K | $-721.0K | $-617.0K | $29.5M | $37.1M | $67.9M | $118.8M | $159.4M | $213.9M | $266.1M | ||
| Rent And Landing Fees | $-664.0K | $-721.0K | $-617.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $13.0M | $11.3M | $13.9M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BCRX | $7.70 | -3.3% | 6.62M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get BioCryst Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW